HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Serum protein profiling to identify high-risk neuroblastoma: preclinical relevance of blood-based biomarkers.

AbstractINTRODUCTION:
Development of early detection assays for advanced stage neuroblastoma (NB) remains elusive. We have previously shown that serum protein profiling technologies can differentiate healthy from NB children. As various sources of patient related bias exist in serum proteins, we hypothesized a well controlled animal model may provide a better method to identify tumor blood-based markers during NB progression.
METHODS:
Tumors were induced in the left kidneys of nude mice by the injection of cultured human NB cells (10(6)). Sera were collected from control and tumor-bearing mice at 2, 4, and 6 wk. Albumin-depleted sera were subjected to comparative proteomic profiling using 2D gel electrophoresis. Paired samples at each time point were analyzed and differentially expressed serum proteins were identified by mass spectrometry. Additionally, sera proteomic analysis from children with Stage IV NB and healthy controls were performed.
RESULTS:
Overexpression of five mouse serum proteins [alpha(1)-acid glycoprotein, alpha(1)-antitrypsin, alpha(2)-macroglobulin, serum amyloid P-component, and serum amyloid A) were found only in NB-bearing mice. Changes in protein abundance were found to increase 2.5-fold (P < or = 0.05) between 2-, 4-, and 6-wk old mice. Underexpression of immunoglobulin kappa chain constant region was observed in the sera of tumor bearing mice compared with controls (2.5-fold, P < or = 0.05). Among NB patients, alpha(1)-acid glycoprotein, apolipoprotein A-IV, haptoglobin, and serum amyloid A were found to be up-regulated.
CONCLUSIONS:
We identified distinct acute phase proteins that show up-regulation in both an animal tumor model and high-risk NB patients. As these serum proteins have been recognized as markers of tumor progression and prognosis in human malignancies, the validation of these polypeptides may enable serum proteomic profiling to become a valuable tool for identifying high-risk NB.
AuthorsJohn A Sandoval, Katharyn E Turner, Derek J Hoelz, Frederick J Rescorla, Robert J Hickey, Linda H Malkas
JournalThe Journal of surgical research (J Surg Res) Vol. 142 Issue 2 Pg. 268-74 (Oct 2007) ISSN: 0022-4804 [Print] United States
PMID17727886 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
Topics
  • Animals
  • Biomarkers, Tumor (analysis, blood)
  • Brain Neoplasms (blood, diagnosis, epidemiology)
  • Cell Line, Tumor
  • Child
  • Early Diagnosis
  • Electrophoresis, Gel, Two-Dimensional
  • Female
  • Humans
  • Kidney
  • Mass Spectrometry
  • Mice
  • Mice, Nude
  • Neoplasm Staging
  • Neoplasm Transplantation
  • Neuroblastoma (blood, diagnosis, epidemiology)
  • Proteomics (methods)
  • Risk Factors
  • Transplantation, Heterologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: